Abstract
The trend toward the production of high purity factor VIII concentrates for clinical use is still in progress. Although all plasma derivatives must undergo viral inactivation procedures, the possibility of transmission of viral diseases is not completely eliminated. In order to reduce such risk, we have included double virus inactivation in the procedure of factor VIII concentrate production. In a scale-up procedure for isolation of factor VIII from cryoprecipitate, two methods were used. The first is based on the chromatographic purification of factor VIII after pasteurization of cryoprecipitate solution and solvent/detergent (S/D) inactivation of viruses. The second is based on multistep precipitation of factor VIII by sodium chloride and glycine. Viral inactivation was performed by combination of S/D treatment and heating of final freeze-dried product 30 min at 100°C. The typical yield of factor VIII activity in the freeze-dried product was about 20% for the first method, and 25–30% for the second. Electrophoretic analyses of both factor VIII preparations by SDS-PAGE and IEF show very low content of contaminant proteins, in accordance with observed 400–650-fold increase of their specific activity over plasma. Both factor VIII products were stable in the liquid state for more than 24 h at room temperature. The final products, after double viral inactivation, are considered to be suitable for clinical evaluations.
Similar content being viewed by others
References
Pool, J. G., Hershgold, E. J., and Pappenhagen, A. R. (1964),Nature 203, 312.
Sgouris, T. and Wickerhouser, M. (1973),Transfusion 13, 399–404.
Schwinn, H., Smith, A., and Wolter, D. (1989),Arzneimittelforschung/Drug Res. 39, 1302–1305.
Brettler, D. B., Forserberg, A. D., Levine, P. H., Fetillo, J., Lamon, K., and Sullivan, J. (1989),Blood 73, 1859–1863.
White, G. C., Matthews, T. J., Weinhold, K.J., Haynes, B. F., Cromartie, H. L., and McMillan, C. W. (1986),Lancet 1, 611, 612.
Van den Berg, W., Ten Cate, J. W., Breederveld, C., and Goudsmit, J. (1986),Lancet 1, 803, 804.
Schimpf, K., Mannucci, P. M., Kreuz, W., Brackmann, H. H., De Rosa, V., Kraus, B., et al. (1987),N. Engl. J. Med. 316, 188–922.
Schimpf, K., Brackmann, H. H., and Kreuz, W. (1989),N. Engl. J. Med. 321, 1148–1152.
Horowitz, M. S., Horowitz, B., Rooks, C., and Hilgartner, M. W. (1988),Lancet ii, 186–189.
Gazengel, C. (1989),Thromb. Haemost. 62, 455., XIIth Congress ISTH, Tokyo, August 1989, abstract 1467.
Mannucci, P. M. (1993),Vox Sang. 64, 197–203.
Franco, E., Divizie, M., De Santis, M. E., Azzi, A., and Borri, M. G. (1992), XX Int Congr. World Fed. Haemophil., p. 23.
Rubinstein, A. I., Rubinstein, D. B., and Tom, W. (1994),Vox Sang. 66, 295–296.
Burnouf, T., Burnouf-Radosevich, J., Huart, J., and Gouldemand, M. (1991),Vox Sang. 60, 8–15.
Myers, R., Wickerhauser, M., Charamella, L., Simon, L., Nummy, W. and Brodniewicz-Proba, T. (1991),Vox Sang. 60, 141–147.
Proctor, R. R. and Rapaport, S. I. (1961),Am. J. Clin. Pathol. 36, 212–219.
The United States Pharmacopeia, 22nd rev. ed., 1995, 1718.
Bradford, M. M. (1976),Anal. Biochem. 72, 248–345.
Horowitz, B., Wiebe, M. E., Lippin, A., and Stryker, M. H. (1985),Transfusion 25, 516–522.
Laemmli, U. K. (1970),Nature 227, 680–685.
Brettler, D. B. and Levine, P. H. (1989),Blood 73, 2067–2073.
Pierce, G. C., Lusher, J. M., and Brownstein, A. P. (1989),JAMA 261, 3434–3438.
Aledort, L. M., Hilgartner, M., and Lipton, R. A. (1988),N. Engl. J. Med. 319, 1017.
Arrighi, S., Pacenti, L., and Borri, M. G. (1993),Vox Sang. 64, 13–18.
Stryker, M.H., Horowitz, M. S., Lipton, R. A., Orme, T. W., Vandersande, J., and Horowitz, B. (1985),Thromb. Haemostasis (Abstract).54, 20.
Edwards, C. A., Piet, M. P. J., Chin, S., and Horowitz, B. (1987),Vox Sang. 52, 53–59.
Woese, C. (1960),Ann. N.Y. Acad. Sci. 83, 741–750.
Helenius, A. and Simons, K. (1972),J. Biol. Chem. 247, 3656–3661.
Foster, P. R., Dickson, A. J., and Mcquillon, T. A. (1982),Vox Sang. 42, 180–189.
Seghatchian, M. J., Kemball-Cook, G., and Barrowcliffe, T. W. (1979),Haemostasis 8, 106–116.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Branović, K., Gebauer, B., Treščec, A. et al. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation. Appl Biochem Biotechnol 69, 99–111 (1998). https://doi.org/10.1007/BF02919392
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02919392